Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens

Mark L Gonzalgo, Christian P. Pavlovich, Shing M. Lee, William G. Nelson

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Purpose: We assess the feasibility of a urinary test for prostate cancer detection in a high-risk patient cohort based on methylation-specific PCR analysis of the π class glutathione S-transferase (GSTP1) gene promoter. Experimental Design: A total of 45 men underwent transrectal ultrasound-guided biopsy of the prostate for suspected malignancy. Clean-catch voided urine specimens were prospectively collected from each patient immediately after biopsy. Genomic DNA was isolated from urine specimens and subjected to sodium bisulfite modification. Methylation of the GSTP1 promoter was examined in a blinded manner by methylation-specific PCR analysis and correlated with pathology results, and clinical information was obtained from the patient record. Results: Methylation of GSTP1 in the urine was detected in a total of 18 of 36 (50%) informative cases. A total of 7 of 18 (39%) patients with prostate adenocarcinoma identified on their initial biopsy had detectable urinary GSTP1 methylation (58% sensitivity among informative cases). Abnormal urinary GSTP1 methylation was also detected in 7 of 21 (33%) patients without evidence of cancer on biopsy and in 4 of 6 (67%) patients diagnosed with atypia or high-grade prostatic intraepithelial neoplasia. Conclusions: We have demonstrated the feasibility of a novel, noninvasive molecular approach for the detection of epigenetic changes associated with prostate cancer. A screening test based on GSTP1 methylation in the urine specimens of patients with suspected prostate malignancy may be a useful adjunct to serum screening tests and digital rectal examination findings for identification of men at increased risk of harboring cancer despite a negative biopsy. This molecular assay has potential application for stratification of patients into low- and high-risk groups for surveillance versus repeat biopsy.

Original languageEnglish (US)
Pages (from-to)2673-2677
Number of pages5
JournalClinical Cancer Research
Volume9
Issue number7
StatePublished - Jul 1 2003
Externally publishedYes

Fingerprint

Methylation
Prostatic Neoplasms
Urine
Biopsy
Prostate
Neoplasms
Prostatic Intraepithelial Neoplasia
Digital Rectal Examination
Polymerase Chain Reaction
Clinical Pathology
Glutathione Transferase
Epigenomics
Adenocarcinoma
Research Design
DNA
Serum
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. / Gonzalgo, Mark L; Pavlovich, Christian P.; Lee, Shing M.; Nelson, William G.

In: Clinical Cancer Research, Vol. 9, No. 7, 01.07.2003, p. 2673-2677.

Research output: Contribution to journalArticle

Gonzalgo, Mark L ; Pavlovich, Christian P. ; Lee, Shing M. ; Nelson, William G. / Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. In: Clinical Cancer Research. 2003 ; Vol. 9, No. 7. pp. 2673-2677.
@article{ca7166c342b34e88b56ed3b2228bae3e,
title = "Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens",
abstract = "Purpose: We assess the feasibility of a urinary test for prostate cancer detection in a high-risk patient cohort based on methylation-specific PCR analysis of the π class glutathione S-transferase (GSTP1) gene promoter. Experimental Design: A total of 45 men underwent transrectal ultrasound-guided biopsy of the prostate for suspected malignancy. Clean-catch voided urine specimens were prospectively collected from each patient immediately after biopsy. Genomic DNA was isolated from urine specimens and subjected to sodium bisulfite modification. Methylation of the GSTP1 promoter was examined in a blinded manner by methylation-specific PCR analysis and correlated with pathology results, and clinical information was obtained from the patient record. Results: Methylation of GSTP1 in the urine was detected in a total of 18 of 36 (50{\%}) informative cases. A total of 7 of 18 (39{\%}) patients with prostate adenocarcinoma identified on their initial biopsy had detectable urinary GSTP1 methylation (58{\%} sensitivity among informative cases). Abnormal urinary GSTP1 methylation was also detected in 7 of 21 (33{\%}) patients without evidence of cancer on biopsy and in 4 of 6 (67{\%}) patients diagnosed with atypia or high-grade prostatic intraepithelial neoplasia. Conclusions: We have demonstrated the feasibility of a novel, noninvasive molecular approach for the detection of epigenetic changes associated with prostate cancer. A screening test based on GSTP1 methylation in the urine specimens of patients with suspected prostate malignancy may be a useful adjunct to serum screening tests and digital rectal examination findings for identification of men at increased risk of harboring cancer despite a negative biopsy. This molecular assay has potential application for stratification of patients into low- and high-risk groups for surveillance versus repeat biopsy.",
author = "Gonzalgo, {Mark L} and Pavlovich, {Christian P.} and Lee, {Shing M.} and Nelson, {William G.}",
year = "2003",
month = "7",
day = "1",
language = "English (US)",
volume = "9",
pages = "2673--2677",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens

AU - Gonzalgo, Mark L

AU - Pavlovich, Christian P.

AU - Lee, Shing M.

AU - Nelson, William G.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Purpose: We assess the feasibility of a urinary test for prostate cancer detection in a high-risk patient cohort based on methylation-specific PCR analysis of the π class glutathione S-transferase (GSTP1) gene promoter. Experimental Design: A total of 45 men underwent transrectal ultrasound-guided biopsy of the prostate for suspected malignancy. Clean-catch voided urine specimens were prospectively collected from each patient immediately after biopsy. Genomic DNA was isolated from urine specimens and subjected to sodium bisulfite modification. Methylation of the GSTP1 promoter was examined in a blinded manner by methylation-specific PCR analysis and correlated with pathology results, and clinical information was obtained from the patient record. Results: Methylation of GSTP1 in the urine was detected in a total of 18 of 36 (50%) informative cases. A total of 7 of 18 (39%) patients with prostate adenocarcinoma identified on their initial biopsy had detectable urinary GSTP1 methylation (58% sensitivity among informative cases). Abnormal urinary GSTP1 methylation was also detected in 7 of 21 (33%) patients without evidence of cancer on biopsy and in 4 of 6 (67%) patients diagnosed with atypia or high-grade prostatic intraepithelial neoplasia. Conclusions: We have demonstrated the feasibility of a novel, noninvasive molecular approach for the detection of epigenetic changes associated with prostate cancer. A screening test based on GSTP1 methylation in the urine specimens of patients with suspected prostate malignancy may be a useful adjunct to serum screening tests and digital rectal examination findings for identification of men at increased risk of harboring cancer despite a negative biopsy. This molecular assay has potential application for stratification of patients into low- and high-risk groups for surveillance versus repeat biopsy.

AB - Purpose: We assess the feasibility of a urinary test for prostate cancer detection in a high-risk patient cohort based on methylation-specific PCR analysis of the π class glutathione S-transferase (GSTP1) gene promoter. Experimental Design: A total of 45 men underwent transrectal ultrasound-guided biopsy of the prostate for suspected malignancy. Clean-catch voided urine specimens were prospectively collected from each patient immediately after biopsy. Genomic DNA was isolated from urine specimens and subjected to sodium bisulfite modification. Methylation of the GSTP1 promoter was examined in a blinded manner by methylation-specific PCR analysis and correlated with pathology results, and clinical information was obtained from the patient record. Results: Methylation of GSTP1 in the urine was detected in a total of 18 of 36 (50%) informative cases. A total of 7 of 18 (39%) patients with prostate adenocarcinoma identified on their initial biopsy had detectable urinary GSTP1 methylation (58% sensitivity among informative cases). Abnormal urinary GSTP1 methylation was also detected in 7 of 21 (33%) patients without evidence of cancer on biopsy and in 4 of 6 (67%) patients diagnosed with atypia or high-grade prostatic intraepithelial neoplasia. Conclusions: We have demonstrated the feasibility of a novel, noninvasive molecular approach for the detection of epigenetic changes associated with prostate cancer. A screening test based on GSTP1 methylation in the urine specimens of patients with suspected prostate malignancy may be a useful adjunct to serum screening tests and digital rectal examination findings for identification of men at increased risk of harboring cancer despite a negative biopsy. This molecular assay has potential application for stratification of patients into low- and high-risk groups for surveillance versus repeat biopsy.

UR - http://www.scopus.com/inward/record.url?scp=0037817323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037817323&partnerID=8YFLogxK

M3 - Article

C2 - 12855646

AN - SCOPUS:0037817323

VL - 9

SP - 2673

EP - 2677

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -